Gene · 6385
SDC4: syndecan 4
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. SDC4: syndecan 4. Genes, record 6385. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/6385
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P31431 | Syndecan-4 | 198 | 5 | Ensembl, GeneID, HGNC |
Source UniProt
Patents75
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| WO 2026209808 A1 | 2026-10-08 | 7 | P31431 | Espacenet |
| JP 2026090543 A | 2026-06-02 | 756 | P31431 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 66158 | P31431 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 9161 | P31431 | Espacenet |
| WO 2025228986 A1 | 2025-11-06 | 14 | P31431 | Espacenet |
| EP 4644537 A1 | 2025-11-05 | 14 | P31431 | Espacenet |
| EP 4641202 A2 | 2025-10-29 | 525 | P31431 | Espacenet |
| EP 4641203 A2 | 2025-10-29 | 271 | P31431 | Espacenet |
| JP 2025517967 A | 2025-06-12 | 271 | P31431 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 9161 | P31431 | Espacenet |
1 to 10 of 75
See all 75 patentsDrugs1
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action |
|---|---|---|---|
| REPOTRECTINIB | CHEMBL4298138 | ROS1-SDC4 inhibitor | INHIBITOR |
Source ChEMBL
Trials9
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07599007 | REPOTRECTINIB | ClinicalTrials.gov | ||
| NCT06552234 | REPOTRECTINIB | PHASE2 | ClinicalTrials.gov | |
| NCT06408168 | REPOTRECTINIB | PHASE2 | ClinicalTrials.gov | |
| NCT06315010 | REPOTRECTINIB | PHASE2 | ClinicalTrials.gov | |
| NCT06140836 | REPOTRECTINIB | PHASE3 | ClinicalTrials.gov | |
| NCT05004116 | REPOTRECTINIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT04772235 | REPOTRECTINIB | PHASE1 | ClinicalTrials.gov | |
| NCT04094610 | REPOTRECTINIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT03093116 | REPOTRECTINIB | PHASE1/PHASE2 | ClinicalTrials.gov |
NIH grants1,634
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | SDC4 papers | Newest fiscal year |
|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | 19 | 2025 |
| P30CA046934 | University of Colorado Cancer Center Support Grant | 9 | 2025 |
| P30EY016665 | Core Grant for Vision Research | 9 | 2025 |
| R01CA164273 | Overcoming Resistance Mechanisms to Anaplastic Lymphoma Kinase Inhibitors | 7 | 2025 |
| K12CA086913 | Paul Calabresi Award in Clinical Oncology Research | 6 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 5 | 2025 |
| P30DK056336 | UAB Nutrition Obesity Research Center (NORC) | 5 | 2025 |
| P30EY010572 | Ophthalmology Core Facility | 5 | 2025 |
| P30CA014520 | UW Comprehensive Cancer Center Support | 4 | 2025 |
| P30CA068485 | Cancer Center Support Grant | 4 | 2025 |
1 to 10 of 1,634Source NIH's project files
See all 1,634 nih grantsPapers3,062
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Glycocalyx and Metabolomic Profiles After Trauma Across Age and Frailty Groups: A Pilot Study. | J Surg Res | 2026 | 42785046 | PubTator, text mining | PubMed |
| Exploring the impact of syndecans in prostate cancer: Stage-specific roles and therapeutic implications. | Eur J Cell Biol | 2026 | 42721521 | PubTator, text mining | PubMed |
| Myofibroblastic CAF and Malignant Ductal Cell Crosstalk Drives Epithelial-Mesenchymal Transition and Progression in Pancreatic Ductal Adenocarcinoma via THBS2-SDC/Integrin Axes. | Int J Mol Sci | 2026 | 42589604 | PubTator, text mining | PubMed |
| Mechanosensors Collaborate to Regulate DNA Damage Repair in Hepatocellular Carcinoma. | Cancer Res | 2026 | 42525956 | PubTator, text mining | PubMed |
| Single-cell and spatial transcriptomics uncover a THBS2⁺ CAF-KRT17⁺ malignant cell axis drives progression and immunotherapy resistance in pancreatic cancer. | Transl Oncol | 2026 | 42520475 | PubTator, text mining | PubMed |
| ANGPTL4 in gestational diabetes: a diagnostic biomarker linked to placental senescence. | Funct Integr Genomics | 2026 | 42487020 | PubTator, text mining | PubMed |
| Analytical and clinical validation of a novel proximity extension assay-based plasma biomarker panel in a cohort of prevalent neurodegenerative dementias. | Alzheimers Res Ther | 2026 | 42436533 | PubTator, text mining | PubMed |
| Deep Proteomic Analysis With Machine Learning Identifies Aqueous Humor Biomarkers of ADAMTSL4-associated Congenital Ectopia Lentis. | Invest Ophthalmol Vis Sci | 2026 | 42423409 | PubTator, text mining | PubMed |
| Heparan Sulfate Proteoglycans in Immunity. | Proteoglycan Res | 2026 | 42383138 | PubTator, text mining | PubMed |
| Association of circulating biomarkers of glycocalyx injury, sirtuin 1, and NFκB p65 in individuals with type 2 diabetes and concurrent arterial hypertension. | Microvasc Res | 2026 | 42320824 | PubTator, text mining | PubMed |
1 to 10 of 3,062
See all 3,062 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/6385
GET https://conductscience.org/api/genes/v1/6385/patents?page=2